User: Guest

PHARMACEUTICAL CONTRACT MANUFACTURING

Global Market Trajectory & Analytics

MCP-1535

VALIDATED EXECUTIVE ENGAGEMENTS

POOL + OUTREACH

3679
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

662
Interactions with Platform & by Email

PARTICIPANTS

112
Unique # Participated

VALIDATIONS

51
Responses Validated*
* Login to view program details and full enterprise executive list.

DATE

OCTOBER 2020

TABLES

162

PAGES

528

EDITION

18

PRICE

USD $4950


The global market for Pharmaceutical Contract Manufacturing is expected to slump by -1.4% in the year 2020 and thereafter recover and grow on the back of newly emerging dynamics to reach US$136.5 billion by the year 2027, trailing a post COVID-19 CAGR 4.6% over the analysis period 2020 through 2027. With the pandemic exposing the weakness of health systems worldwide, governments are stepping up the emphasis and policy led support for strengthening their healthcare infrastructure. Governments worldwide have voiced plans to strengthen healthcare system. Already governments have announced budgetary support to strengthen the health system's response to COVID-19. From stepping up research activities, constructing new hospitals, adding more capacity in the form of additional beds, procuring critical care life support devices such as ventilators to training, hiring healthcare staff, several measures are being implemented. The disruption and chaos unleashed by the pandemic has led pharmaceutical companies to rethink their supply chains and outsourcing strategies. The pandemic's impact on pharma supply chains was largely evident in the broken and stranded logistics as countries world over closed their borders, although late to prevent the further spread of the infection. Complete disruption and halting of the transportation and logistics sector temporarily impacted pharmaceutical drug production in countries heavily dependent on imports for active pharmaceutical ingredients (APIs).


The pandemic has exposed the risk of over dependence on a single country for raw materials. China supplies a lion's share of pharma raw materials demanded worldwide. For several antibiotics and drugs that treat high blood pressure, China is the sole source of API in the country. Over the last decade, the number of facilities in China supplying active pharmaceutical ingredients (APIs) to the U.S. alone has doubled since 2010 highlighting the blunder made by the U.S. government in prioritizing the Chinese manufacturing industry over its own. In addition, decisions take by governments to ban exports of certain high value and critically important ingredients in a proactive move to mitigate drug and medical device supply shortages in domestic markets. In the world's most populous country India, for instance, fears over the pandemic spread and anticipated increase in demand for drugs the led the Indian government to ban the exports of over 26 pharma ingredients. These protectionist trade policies aimed at securing domestic pharmaceutical supplies has severely undermined global equitable drug availability and access. Supply chain management over the long-term is in for some of the biggest changes not witnessed in over a century. Countries world over are encouraging pharma companies to secure themselves against volatility in supplies from Asia and from China in particular.


While an immediate shift in pharmaceutical chemical supply lines is not a pragmatic possibility, the change is expected to gradually sink in. Spearheading the new self-sufficient sentiment in the global drug manufacturing space is India, country which is ambitiously focused on turning a crisis into an opportunity by rethinking and rejuvenating its pharmaceutical supply chain management practices and ideologies. Going forward over the long-term decisions to outsource manufacturing activities will be governed by more than just cost efficiency benefit. As companies emerge wiser from the lessons taught by the pandemic outsourcing drug manufacturing will mean greater focus will be shed on maintaining good reactive capacity close to where it is needed. Also, companies will now begin to outsource manufacturing to multiple countries and regions to ensure resilience in case of disasters similar to the current healthcare crisis or natural disasters. Until now, pharma companies have leveraged outsourcing as a great way to take advantage of cheap labor and raw materials available in countries like China. As the world tries to disengage dependence on China, nearshoring as a sub-set of offshoring is gaining whole new significance and reenergized focus. The closer manufacturing partners are to the home country, greater will be level of control over quality and lesser will be vulnerability to disruptions. Communication becomes easier, time-to-market is significantly reduced, chances of errors and product recalls become smaller, and control, flexibility and agility are increased x times. Vulnerability to transport disruptions also becomes significantly lower. Also nearshoring to contract manufacturers in the same time zone means lesser regulatory bottlenecks. In addition to protecting against unforeseen disaster scenarios and disruptions, nearshoring also reduces quality defects, random interruptions in manufacturing processes, order processing difficulties, untimely delivery of products and mismatch between market demand and supplier responsiveness. Nearshoring is increasingly perceived to be a part of the bigger reshoring trend set into motion by the COVID-19 pandemic. In addition, to mitigate the effects of supply chain disruptions, pharmaceutical companies are increasingly recalibrated their strategies by greater insourcing and nearshoring of core products, and outsourcing non-core products and developing offshore insourcing capabilities through 'captives'. The B2G is poised to balloon into a major trend as public-private partnerships come to the spotlight as countries initiate policy changes to bring back domestic production.

Aenova Group; Ajinomoto Althea, Inc.; Albany Molecular Research Inc.; Alcami Corporation; Baxter International, Inc.; Boehringer Ingelheim GmbH; Catalent Pharma Solutions, Inc.; Cobra Biologics Holding AB; CordenPharma International; Dishman Group; Famar Health Care Services; Hospira, Inc.; Jubilant Life Sciences Limited; Kemwell Biopharma Pvt. Ltd.; Lonza Group Ltd.; LTS Lohmann Therapie-Systeme AG; NextPharma Technologies Holding Ltd.; Nipro Pharma Corporation; Recipharm AB; Vetter Pharma International GmbH
» Product Type (API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations, Other Product Types) » Application (Pharmaceutical, Biopharmaceutical) » End-Use (Sterile, Non-Sterile)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

ACTIVE CLIENT

INACTIVE CLIENT

ACTIVE PANELIST

INACTIVE PANELIST

OPT-INS

FEATURED COMPANIES

Registration is required to access our data stacks.

WORLD BRANDS

Registration is required to access our data stacks.

EXECUTIVES ENGAGED

Registration is required to access our data stacks.

KEY DIFFERENTIATORS

We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.

* A review of 262 off-the-shelf market report publishers worldwide.

WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.

Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.

Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)

A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.

Where relevent and possible we present competitive brands.

Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.

Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.

Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.

We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.

  
05
1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Pharmaceutical Contract Manufacturing A Prelude
COVID-19 Breaks All Things Normal, Pushes Pharmaceutical Industry Into an Era of Change
COVID-19 Exposes US Pharmaceutical Makers to Risk of Supply Shortages
US Federal Government & FDA Take Unprecedented, Bold Steps to Deal with Shortage of Pharmaceuticals
What Does this Spell for Pharmaceutical Outsourcing & Contract Manufacturing?
Market Outlook
The US and Europe Constitute the Largest Markets for PCM
Asia-Pacific to Drive the PCM Market Growth
Competition
M&A Activity High in the Contract Manufacturing Space
2. FOCUS ON SELECT PLAYERS
Recent Market Activity
3. MARKET TRENDS & DRIVERS
Strong Rise in Pharmaceutical Sales to Drive Demand for Pharmaceutical Contract Manufacturing
EXHIBIT: Global Prescription Drug Sales (In US$ Billion) for the Years 2017, 2019, 2021, 2023 & 2025
Emergence of Outsourcing Trend Bodes Well for CDMOs
Pharmaceutical Contract Manufacturers Adopt Advanced Manufacturing Technologies
Embracing Emerging Technologies
Exploring & Exploiting New Technologies for Rich Dividends
Rapid Growth of Generic Drugs Drives Demand for Pharma Contract Manufacturing
EXHIBIT: Leading Drugs Facing Patent Expiry in the US in 2020
EXHIBIT: Global Generic Drugs Market Size (in $ Billion) for the Years 2016, 2019, 2020 & 2025
Increasing Significance of Biologic Drugs Fuels Innovations Supports Demand for Pharmaceutical Contract Manufacturing Market
EXHIBIT: Global Biologic Drugs Market Size (in US$ Billion) for the Years 2019, 2022 & 2025
Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth
EXHIBIT: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT: World Diabetes and Population Statistics (2019, 2030 & 2045)
Persistent Increase in Pharmaceutical R&D Bodes Well for PCM
Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
Increasing Sales of OTC Drugs Presents an Opportunity for Pharma Contract Manufacturing Market
EXHIBIT: Global OTC Drugs Market Breakdown by Product (in %): 2020E
Increasing Outsourcing of Clinical Trials to Emerging Markets
New Technology Promises to Improve Sterile Manufacturing Process
Serialization Drives New Design Developments in Pharma Sector
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for API/Bulk Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for API/Bulk Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for API/Bulk Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Advanced Drug Delivery Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Advanced Drug Delivery Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Advanced Drug Delivery Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Packaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Finished Dose Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Finished Dose Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Finished Dose Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Biopharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Biopharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Biopharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Sterile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Non-Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
World Historic Review for Non-Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
World 15-Year Perspective for Non-Sterile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
GEOGRAPHIC MARKET ANALYSIS
United States
USA Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
USA Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
USA 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
USA Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
USA 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
USA Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
USA 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Canada
Canada Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Canada Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Canada 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Canada Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Canada 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Canada Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Canada 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Japan
Japan Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Japan Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Japan 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Japan Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Japan 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Japan Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Japan 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
China
China Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
China Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
China 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
China Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
China Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
China 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
China Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
China Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
China 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Europe
Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
Europe Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Europe Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Europe Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Europe Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
France
France Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
France Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
France 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
France Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
France Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
France 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
France Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
France Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
France 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Germany
Germany Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Germany Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Germany 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Germany Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Germany 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Germany Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Germany 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Italy
Italy Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Italy Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Italy 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Italy Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Italy 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Italy Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Italy 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
United Kingdom
UK Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
UK Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
UK 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
UK Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
UK 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
UK Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
UK 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Rest of Europe
Rest of Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Asia-Pacific
Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for India and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
India
India Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
India Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
India 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
India Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
India Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
India 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
India Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
India Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
India 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Rest of Asia-Pacific
Rest of Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
Rest of Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
Rest of Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Rest of World
Rest of World Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
Rest of World Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
Total Companies Profiled : 192

Click here to request a full table of contents and more details on this project.

INSIDER ACCESS TO

 METHODOLOGY  QUESTIONNAIRE  INFLUENCER NETWORK

Registration is required to access our data stacks.

RESEARCH PANEL

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.

  • Complimentary previews of full stack research data for participated
  • Insider access to research programs including engagements and stats from other panelists
  • Unlimited research credits of $1000 per participated project
  • Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
  • Interact with other panelists via our MarketGlassTM Data Exchange Platform*
  • BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*

* Complete details will be shared with panelists upon formal acceptance.

 GLOBAL EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com